Potent And Highly Soluble Pegylated Compstatin Peptide
Inhibit complement activation by targeting protein C3, the converging point of all three complement activation pathwaysPossess highly improved aqueous solubility properties and overcome the aggregation limitation for clinical translation of previously known compstatin peptidesPossess significantly improved inhibitory efficacy and retain inhibitory potency, compared to previously known compstatin peptides
None
20180057538
Background Lack of regulation in complement response is implicated in the pathology of several disorders, such as age-related macular degeneration, paroxysmal nocturnal hemoglobinurea, rare kidney diseases, chronic obstructive pulmonary disease, lupus, rheumatoid arthritis, asthma, adult respiratory distress syndrome, hemolytic anemia, rejection of xenotransplantation, stroke, heart attack, and ischemia reperfusion injuries. Regulating complement activation is important to control inflammation, autoimmune diseases, and infections. The compstatin family of peptides have been shown to be potent inhibitors of complement system activation and are promising candidates to become therapeutics for the treatment of age-related macular degeneration, and other complement-mediated diseases. Applications Patent Pending Related Materials Tech ID/UC Case 27122/2017-046-0 Related Cases 2017-046-0
Patent Status
美國
